New FDA Approval: Deucravacitinib (Sotyktu), a First-In-Class Oral, Allosteric Tyrosine Kinase 2 Inhibitor

In September 2022, deucravacitinib (Sotyktu), a first-in-class oral, allosteric tyrosine kinase 2 (TYK2) inhibitor for moderate-to-severe plaque psoriasis, was approved by the FDA. Aside from its first-in-class mechanism of action, it is the first approved de novo deuterated drug.

This premium deep dive into deucravacitinib includes:

  • the industry context
  • the clinical data
  • the target rationale
  • the mechanism of action
  • the drug’s origins
deucravacitinib (Sotyktu), deuterated TYK2 inhibitor, Newly approved for patients with plaque psoriasis, Deuteromethylamide suppresses N-demethylation via deuterium kinetic isotope effect, High selectivity for TYK2 over JAK1, JAK2, and JAK3

get free samples and a Premium trial

Premium members get access to our library of hundreds of in-depth reviews on key molecules, ten new reviews each month, novel drug approval coverage, drug discovery company updates, and more:

Join the Drug Hunter mailing list

to get free content and resources weekly. Trusted by > 5,500 drug hunters worldwide. Unsubscribe anytime.


Join Subscribers from